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Lipoxin A (LXA) is a novel eicosanoid, generated by the interactions of lipoxygenases, which has a variety 
of biological actions. When added to human polymorphonuclear leukocytes, LXA stimulated thromboxane 
formation which was monitored as TxB2 by radioimmunoassay. The compound augmented the formation 
of TxA2 stimulated by the ionophore of divalent cations (A23 187). Formation of thromboxane was inhibit- 
ed by two non-steroidal anti-inflammatory drugs (i.e. indomethacin and proglumetacin). Results of the pres- 
ent study indicate that LXA can provoke the release and transformation of endogenous arachidonic acid 
to thromboxane. Moreover, they suggest a relationship between lipoxin A and the formation of cyclooxy- 
genase pathway products. 
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1. INTRODUCTION 
PMN leukocytes play a central role in the im- 
mune system and in inflammatory diseases. PMN 
leukocytes can release lysosomal enzymes, PGs, 
Txs and lipoxygenase products [l-4] when ex- 
posed to the calcium ionophore A23187. TxA2 is 
a biologically active labile molecule which can be 
formed by PMN leukocytes as well as 
macrophages and platelets [5-71. TxA2 is en- 
zymatically derived from arachidonic acid and in 
aqueous media a molecule of water is rapidly add- 
ed to TxA2 and the stable endoproduct TxB2 is 
formed. 
TxA2 is believed to be the product of the 
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cyclooxygenase pathway in PMN leukocytes, to in- 
duce platelet aggregation, and provoke contraction 
in several tissues [8-lo]. The conversion of 
arachidonic acid into various biologically active 
products is accomplished by cyclooxygenase and 
lipooxygenase pathways. 
Recent studies have indicated that polyun- 
saturated fatty acids and their metabolites are in- 
volved in the functions of leukocytes [l l-131. The 
trihydroxytetraenes are a novel series of ox- 
ygenated derivatives formed from arachidonic acid 
by human leukocytes. The structure of the major 
compound was established and proved to be 
SS,6R,15S-trihydroxy-7,9,13-trans-1 l-cis-eicosa- 
tetraenoic acid [ 1 l-171. When added to human 
PMN leukocytes LXA stimulates chemotaxis 
without provoking aggregation [ 181. Human 
natural killer cells exposed to LXA are unable to 
provoke target cell lysis [19]. 
Moreover, LXA also provokes contraction of 
parenchymal strips and stimulates microvascular 
changes [20]. In the presence study we have deter- 
mined the influence of LXA on TxA2 (detected as 
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release of TxB2) by human peripheral blood de- 
rived polymorphonuclear cells in vitro. 
2. MATERIALS AND METHODS 
or A23187 and determination of TxB2 level. Its 
complete mode of action as that of other non- 
steroidal, anti-inflammatory drugs, remains to be 
fully elucidated. 
2.1. Collection of blood and isolation of PA4N 2.3. Calcium ionophore A23187 
leukocytes 
Blood was obtained from healthy donors and 
collected in polypropylene tubes containing suffi- 
cient heparin to obtain a final concentration of 
20 U/ml. Tests were performed immediately after 
collection. PMN leukocytes were isolated as in 
[21]. Briefly, whole blood was centrifuged over 
Ficoll-Hypaque in 2% dextran for 30 min at room 
temperature [21]. After washing the cells twice 
with buffered saline, the red cells were lysed by 
distilled water, the remaining cells were washed 
and resuspended in Gey’s buffer and viability ex- 
amined by trypan blue-exclusion method. The cells 
were incubated at lo6 per ml at 37°C in triplicate. 
The cell suspensions consisted of more than 94% 
PMN leukocytes. Prior to culture the cells were 
counted in a Burker counting chamber. The cell 
preparation had a PMN to platelet ratio of 10 : 1 or 
less. Samples were treated with LXA at different 
concentrations (lOA -lo-’ M), the controls receiv- 
ed methanol at the same concentration of LXA 
(10d4) and TxB2 was determined utilizing the con- 
ditions described by Jakschik et al. [22]. The in- 
cubations were performed in triplicate and TxB2 
was quantitated by radioimmunoassay of the 
resulting supernatants [23]. 
Ionophore (Sigma) was dissolved in dimethyl- 
sulfoxide (DMSO) at 50 mg/ml. Dilutions of the 
ionophore were made directly in medium with 
various final concentrations. In separate tubes, in 
each experiment, cells were exposed to the vehicle 
alone (i.e. DMSO or ethanol) at identical concen- 
trations, to determine non-specific formation or 
inhibition of TxA2 generation by the vehicle. 
The generation of TxA2 was assessed by the ap- 
pearance of its more stable product TxB2 by 
radioimmunoassay as described [ 191. Results are 
expressed as pg/106 cells. Each test and all controls 
were done in triplicate with each donor. 
2.4. Preparation of lipoxin 
2.2. Tested drugs 
Indomethacin is a potent inhibitor of cycloox- 
ygenase [24,25] and was employed as such in the 
present study to assess the cyclooxygenase 
dependence of LXA-induced TxA2 formation. 
Here, incubations were exposed to indomethacin 
(Merck, Sharp & Dohme) at the indicated final 
concentrations (10-7-10-9 M), followed by deter- 
mination of TxB2 levels. Proglumetacin is a 
derivative in which the indolacetic group is linked 
by piperazinic bond to proglumide. This com- 
pound has been shown to be an effective anti- 
inflammatory agent, a cyclooxygenase inhibitor in 
vitro, and displays a gastroprotective activity [26]. 
All incubations were exposed to proglumetacin 
(Merck, Sharp & Dohme) at a final concentration 
of 3 x lo-’ M; followed by addition of either LXA 
LXA was a gift of Dr Charles N. Serhan, 
Hematology Division, Harvard Medical School, 
Boston, MA, USA. Briefly, LXA was isolated 
from suspensions of mixed human leukocytes (i.e., 
neutrophils, eosinophils, basophils, etc.) as 
described [ 14-171. Human leukocytes prepared 
from healthy donors were warmed to 37°C (200 ml 
of 100 x lo6 cells/ml). Next, 15HETE 
(80-100pM) and A23187 (2.5 PM) were added 
simultaneously in ethanol (1% final, v/v), and in- 
cubations were continued for 20 min. Incubations 
were stopped by addition of 2 vols methanol, ex- 
tracted with ether, and subjected to silicic acid 
chromatography. Materials present in the ethyl 
acetate fraction were combined with 11,12,15- 
trihydroxy-5,8, 13-[l-14C]eicosatrienoate and 11, 
14,15-trihydroxy-5,8,12-eicosatrienoate, treated 
with diazomethane, and then subjected to thin- 
layer chromatography. Thin-layer chromato- 
graphy was carried out with plates coated with 
silica gel G and ethyl acetate-2,2,4_trimethylpen- 
tane (5 : 1, v/v) as solvent. The regions containing 
methyl esters exhibiting tetraene UV spectra (see 
[14]) but no radiolabel were collected, and the 
material was eluted from the gel with methanol. 
Samples were pooled and injected onto a reverse- 
phase HPLC column Altex ultrasphere-ODS 10 
nm x 25 cm eluted with 65 : 35 (v/v) at 30 ml/min, 
with the UV detector set at 301 nm. After re- 
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chromatography in the same HPLC system, an 
aliquot of material was subjected to straight-phase 
HPLC employing a Bakerbond chiral column 
(J.T. Baker) with hexane/isopropanol as solvent 
(90: 10, v/v). Free acids were prepared by LiOH 
saponification and ether extraction [24] followed 
by reverse-phase HPLC performed by using 
MeOH/HzO/acetic acid (70: 30: 0.01, v/v). 
The final purity of LXA was assessed by reverse- 
phase HPLC and proved to be 95% LXA with 5% 
of its all truns-isomer (11-trans-LXA). UV spectra 
of separated components were recorded in 
methanol with the use of a Hewlett-Packard 8450A 
spectrophotometer and an absorption coefficient 
of 50000 to determine concentrations. The com- 
pound was subject to analysis by gas 
chromatography/mass spectrophotometry. 
3. RESULTS 
Human PMN cells were assayed for TxA2 for- 
mation in the presence or absence of LXA and 
calcium ionophore. Fig.1 shows the amounts of 
TxB2 (pg/106 cells) released by human PMN 
leukocytes after addition of calcium ionophore 
A23187 at varying concentrations (0.2, 2, 50, and 
100 PM). The amounts of TxB2 released by the cell 
after 1 h incubation was maximum at both 2 and 
50pM (269.81 f 25.6 and 254.72 f 40.2), and 
lower at 0.2pM (122.64 f 32.4). At the highest 
concentration tested, A23187 (100 PM) proved to 
be toxic for the cells, as determined by trypan blue 
exclusion and lower levels of TxB2 were found 
(105.66 +- 30.1). At lower concentrations the 
ionophore was non-toxic and proved to stimulate 
TxA2 formation in a dose- and time-dependent 
fashion. These values were significant when com- 
pared to those obtained from controls (35.85 f 
11.2). 
Results in fig.2 show the amounts of TxB2 
detected in human PMN leukocyte suspension 
following addition of increasing concentrations of 
LXA. Here, TxB2, detected after 1 h incubation, 
was enhanced by increments in the concentration 
of LXA added to the cell suspensions. Again, the 
formation of TxB2 was dose-dependent. The effect 
of LXA was significant at the 1O-4 or 10m5 M dose 
(266.35 f 50.9 and 77.10 -+ 20.2), while at 10m6 or 
lo-’ M it was not significant (51.31 f 11.4 and 
35.04 f 13.0; the control was 35.05 -t 12.8). 
200- 
2 
: 
$ 
0 
Contr 02 2 50 100 
Concentration of A23187 (Mrcro M) 
_J 
Fig.1. TxB2 detected from human PMN leukocyte 
suspensions (lo6 cell/ml) after 1 h incubation with 
calcium ionophore A23187 at four different 
concentrations (0.2,2, 50 and 100 PM). The experiments 
reported here were done in triplicate. 
Fig.3 gives the amounts of TxB2 detected after 
treatment with A23187 (2pM), LXA (10m4 M), 
A23187 (2pM) + LXA (10m4 M) and A23187 
(2 PM) + indomethacin (10m9 M) at different 
periods of incubation (15 and 60 min). The results 
indicate that after 15 min of incubation a signifi- 
cant stimulation of TxA2 (monitored as TxB2) is 
observed with A23187 (372.17 f 41.9) compared 
with the control (40.09 f 10.9). 
Here, the very low dose of indomethacin 
(10e9 M) used, partially reduced the effect of 
A23187 (188.68 + 19.9). At 60 min of incubation, 
the effect of A23187, A23187 + LXA and in- 
domethacin were essentially the same as those at 
15 min (313.68 + 72.4, 358.49 -t 87.0 and 
186.32 f 50.9). The cells were also significantly af- 
fected by LXA (129.72 + 24.5). The control value 
was 58.96 + 20.9. 
Fig.4 gives the percent of TxB2 released follow- 
ing different treatments. Bars B and C show the 
release of TxB2 after treatment with A23187 (2 FM 
and 5 PM, 223.47 f 72.4 and 254.65 f 51.2), 
respectively. A non-statistical significant dif- 
ference was found between them. Bars D and E 
show the release of TxB2 after treatment with 
LXA (low4 and lo-’ M) (224.98 & 57.0 and 
188.54 + 12.1), respectively. We found stimulation 
at 10e5 M only in this experiment. In F, G and H 
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Fig.2. A, control; B, A23187 (2 PM); C, LXA (10e4 M); 
D, LXA (1O-5 M); E, LXA (W6 M; F, LXA (lo-’ M); 
G, LXA (10m4 M) + I (lo-’ M). TxB2 detected from 
human PMN leukocyte suspensions (lo6 cell/ml) after 
1 h incubation with A23187 and LXA at four different 
concentrations (10e4, lo-‘, 10e6 and lo-’ M). 
Indomethacin (I) (lo-’ M) strongly inhibits the TxA2 
after stimulation with LXA (1O-4 M) (G column). The 
experiments reported here were done in triplicate. 
(105.54 + 30.1, 116.43 + 29.9 and 108.54 t- 15.8), 
differences were not found compared to the con- 
trol (99.53 +- 11.2). In I, lo-’ M indomethacin 
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Fig.3. TxB2 detected at various times following 
incubation of human PMN suspensions (lo6 cell/ml) 
and different treatment: A, control; B, A23187 (2 PM); 
C, LXA (1O-4 M); D, A23187 (2pM) + LXA (1O-4 M); 
E, A23187 (2 PM) + indomethacin (10e9 M). Triplicate 
cultures. 
0 
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Fig.4. A, control; B, A23187 (2pM); C, A23187 (5 FM); 
D, LXA (1O-4 M); E, LXA (1O-5 M); F, LXA (W6 M); 
G, LXA (lo-‘M; H, LXA (lo-‘M); I, A23187 
(2fiM) + I (lo-‘M); J, A23187 (2rM) + P (3 x 
lo-’ M); K, A23187 (2pM) + LXA (1O-4 M); L, 
A23187 (2 yM) + LXA (IO-’ M); M, A23187 (2 /IM) + 
LXA (1O-6 M); N, A23187 (2pM) + LXA (lo-’ M); 0, 
A23187 (2,uM) + LXA (1O-4 M) + I (lo-’ M). 
Percentage of TxB2 detected human PMNs after 1 h 
incubation with different treatments. Triplicate cultures. 
I, indomethacin; P, proglumetacin. 
completely inhibited the release of TxB2 induced 
by either A23187 or LXA and reduced the levels 
observed in the absence of stimuli (31.92 f 10.1). 
Here, proglumetacin (3 x IO-’ M) also inhibited 
TxA2 but to a lesser extent than that found with in- 
domethacin (110.80 f 20.7). Results in K, L, M 
and N show the enhancing action of LXA with 
A23 187 which was observed with higher concentra- 
tions of LXA (307.60 f 80.1, 223.10 f 12.1, 
221.60 f 31.0 and 184.04 f 11.1). These interac- 
tions were inhibited by treatment of the cells with 
indomethacin at lo-’ M (31.55 f 15.0) before ad- 
dition of either LXA or A23 187. 
4. DISCUSSION 
Inflammation is, in part, mediated by 
neutrophils which when activated generate 
arachidonate-derived oxygenation products, ox- 
ygen radicals and release lysosomal enzymes 
[27-291. Results of several investigations suggest 
that products of arachidonic acid metabolism have 
modulatory effects on the development of cellular 
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immunity [30-321. Lipoxin A (5S,6R, 154trihy- 
droxy-7,9,13-trans-I 1-cis-eicosatetraenoic acid), a 
newly isolated compound derived from the ox- 
ygenation of arachidonic acid in human 
leukocytes, exerts little or no response in provok- 
ing neutrophil aggregation, but stereospecifically 
stimulates chemotaxis [ 15,181. This compound 
also inhibits the cytotoxic activity of human 
natural killer cells [19]. In this respect it is well 
known that prostaglandins (i.e. PGEz) can inhibit 
many immunological functions in vitro and in vivo 
[33-351. 
In the present study, we have utilized human 
PMN leukocytes as a model system to monitor 
stimulus-induced cyclooxygenase-product forma- 
tion and demonstrate here that human PMN 
leukocytes, exposed to LXA, release relatively high 
amounts of TxA2. Addition of indomethacin to 
the cell suspensions blocked TxA2 formation. 
Based on this observation it is likely that LXA can 
provoke the formation of cyclooxygenase-derived 
products in other cell types. Lipoxin-induced 
prostaglandin formation may be of importance in 
regulating other immunological responses. In addi- 
tion, these results suggest that PMN leukocytes 
may be an additional source of cyclooxygenase 
products in immunopathology. 
Since the stimulation of TxA2 by LXA 
demonstrates that there is a relationship between 
the cyclooxygenase and lipoxygenase pathways we 
hypothesize that the LXA-induced block of 
natural killer cytotoxicity found by Ramsted et al. 
[ 191 can also be achieved, in part, by prostaglan- 
dins which may be released by these or other 
mononuclear cells after formation of LXA. 
Although the stimuli which provoke lipoxin for- 
mation in vivo remain to be determined, the find- 
ing that LXA can provoke the release of 
cyclooxygenase products may be of more general 
importance. 
Further experiments are currently underway to 
clarify the mechanisms of action of lipoxin A. 
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